Platelet Kinetics in Stable Atopic Asthmatic Patients<sup>1,</sup><sup>2</sup>

Taytard, A; Guénard, H.; Vuillemin, L; Bouvot, J. L.; Vergeret, J; Ducassou, D.; Piquet, Y.; Freour, P

doi:10.1164/arrd.1986.134.5.983

Cited by 47 publications

(26 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Traietti et al [19] reported that the frequency of activated platelets in blood smears from asthma patients was increased in arterial as compared with venous blood, implying activation during transit through the asthmatic lung. In agreement with their observations, Taytard et al [20] noted a reduced survival of a proportion of the population of radiolabelled platelets in asthma pa tients, and platelet counts in peripheral blood have been observed to fall during the reaction to inhaled al lergen [21], Yet again, the clinical observations have been contested; Ind et al [22] failed to find any evi dence that radioactively labelled platelets accumu lated within the lung or that platelet destruction was accelerated following exposure of asthma patients to allergen.…”

Section: Platelets In Asthmasupporting

confidence: 90%

Asthma Pharmacology: Industrial/Clinical Interface

Morley¹

1989

Int Arch Allergy Immunol

View full text Add to dashboard Cite

The disease of asthma remains poorly understood. Hence, considerable latitude has been afforded to pharmacologists concerned to identify novel compounds for development as anti-asthma drugs. Compounds can be selected (1) on the basis of known efficacy as bronchodilator (beta-adrenoceptor agonists, parasympatholytics and xanthines) and prophylactic (cromoglycate and ketotifen) or anti-inflammatory (glucocorticosteroids) actions; (2) by reference to current theories of asthma pathogenesis, e.g., inhibition of the formation and action of autoacoids (leukotrienes, platelet-activating factor) or cytokines (GM-CSF, IL-5), or (3) by reference to hitherto unexplored physiological processes (K⁺ channel activation, PDE isoenzyme inhibition, selective immunosuppressive actions). There is a need to test whether the rationale for drug selection is justified. This can only be resolved by study of asthma patients, since normal subjects may respond inappropriately. Thus, normal subjects do not exhibit airway obstruction or airway hyperreactivity and hence do not respond to bronchodilator substances. Similarly, normal subjects respond to platelet-activating factor with a cellular infiltrate in which neutrophils predominate in contrast to atopic asthmatics who exhibit an eosinophilia. It follows that compound discovery and evaluation must be an iterative procedure in which animal studies are supplemented by clinical studies and vice versa. This is most readily achieved by establishing clinical research that is a complementary to preclinical research.

show abstract

Section: Platelets In Asthmasupporting

confidence: 90%

Asthma Pharmacology: Industrial/Clinical Interface

Morley¹

1989

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…The platelet survival curve (radioactivity degradation) showed a biexponential decay pattern, whereas in normal subjects, the curve was monoexponential, suggesting the presence of two highly distinctive populations: one of a short life span (rapidly degrading population) and another of a normal life span. These results suggest the presence of functional or anatomic lesions of platelets in asthmatic patients [23].…”

mentioning

confidence: 60%

Platelet Activation During Allergic Inflammation

Kasperska−Zając

Rogala

2007

Inflammation

View full text Add to dashboard Cite

Blood platelets, apart from their traditional and well-recognised function in haemostasis, play an essential and active role in allergic inflammation e.g. through their participation in cell recruitment from blood to site of immune reactivity as a result of direct interactions with leukocytes, and through the release of inflammatory mediators. Platelet activation may occur during human allergic reactions both systemically and locally at the site of allergic inflammation as a result of an IgE-dependent process and as a secondary event caused by other inflammatory or immune stimuli. Altered platelet function as measured by platelet secretion, expression of surface molecules, aggregation, adhesion or arachidonic acid metabolism has been found in patients suffering from allergic diseases. These blood elements have been implicated in the pathogenesis of allergic diseases associated with the so-called atopic diathesis. This paper reviews the platelet activity and reactivity in allergic inflammation, along with our own findings concerning platelet release reaction and the phenomenon of platelet aggregation in patients with different clinical forms of allergy.

show abstract

“…According to Taytard et al [60], a portion of the platelet population in asthmatics has a significantly reduced survival time. Recent observations also suggest a persistent, partial thrombocytopenia in allergen challenged asthmatics [61], a feature that is particularly evident in asthmatics exhibiting a late asthmatic response (LAR) 3 to 8 hours after Dermatophagoides pteronyssinus challenge [62].…”

Section: Clinical Evidence For a Role Of Platelets In Asthmamentioning

confidence: 99%

The role of platelets in the pathophysiology of asthma

Kornerup

Page

2007

Platelets

View full text Add to dashboard Cite

The incidence of asthma is on the increase worldwide, yet the pathogenesis of this disease is still not fully understood. Many recent drug trials have had disappointing results, thus fuelling the need for more research to be undertaken in this area. Substantial evidence suggests an important role for platelets in various inflammatory diseases, including atherosclerosis, rheumatoid arthritis, eczema, allergic rhinitis and asthma. In asthma, platelets have been found to actively participate in most of its main features, including bronchial hyperresponsiveness, bronchoconstriction, airway inflammation and airway remodelling. It has recently become clear that platelet-release products, as well as the expression of adhesion molecules on the platelet surface and the ability to undergo chemotaxis, are all involved in these processes. This review focuses on both experimental and clinical studies available to date that have investigated the role of platelets in the pathophysiology of asthma. Taken together, the evidence points toward platelets being an attractive new target in the area of asthma research; a target with much-needed novel therapeutic potential.

show abstract

Platelet Kinetics in Stable Atopic Asthmatic Patients^1,²

Cited by 47 publications

References 5 publications

Asthma Pharmacology: Industrial/Clinical Interface

Asthma Pharmacology: Industrial/Clinical Interface

Platelet Activation During Allergic Inflammation

The role of platelets in the pathophysiology of asthma

Contact Info

Product

Resources

About

Platelet Kinetics in Stable Atopic Asthmatic Patients1,2

Cited by 47 publications

References 5 publications

Asthma Pharmacology: Industrial/Clinical Interface

Asthma Pharmacology: Industrial/Clinical Interface

Platelet Activation During Allergic Inflammation

The role of platelets in the pathophysiology of asthma

Contact Info

Product

Resources

About

Platelet Kinetics in Stable Atopic Asthmatic Patients^1,²